BeOne Medicines AG (ONC)Healthcare | Biotechnology | Basel, Switzerland | NasdaqGS
353.09 USD
+4.01
(1.148%)
⇧
(Oct. 14, 2026, 11:33 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 3:47 a.m. EDT
BeOne Medicines offers a rare combination of explosive growth and financial stability in the biotech space. The company has demonstrated remarkable resilience, recovering from a severe 2022 downturn to deliver a nearly 900% cumulative gain over the last nine years. Revenue is expanding at nearly 30% annually, backed by a fortress balance sheet with net cash reserves and healthy margins. While the valuation is premium, the analyst consensus and growth trajectory justify the cost for a long-term portfolio. However, the stock is currently trading slightly below its 50-day moving average, and short-term statistical models hint at minor downside pressure. Investors should view this as a core long-term hold with exceptional growth credentials, while respecting the technical resistance near the 50-day average for shorter-term entries. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.099809 |
| AutoTheta | 0.101439 |
| AutoETS | 0.108561 |
| AutoARIMA | 0.108563 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 8.49 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.183 |
| Excess Kurtosis | -1.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 39.612 |
| Revenue per Share | 55.275 |
| Market Cap | 40,170,516,480 |
| Trailing P/E | 63.16 |
| Forward P/E | 34.44 |
| Beta | 0.61 |
| Profit Margins | 10.70% |
| Previous Name | BeiGene, Ltd. |
| Website | https://beonemedicines.com |
As of Oct. 10, 2026, 3:47 a.m. EDT: Implied volatility remains elevated in the 40-50% range, pricing in significant price swings. Call open interest skews heavily out-of-the-money across November and February expirations, with notable concentration at strikes above 390, signaling speculative bets on substantial upside. Put open interest clusters near the money, suggesting institutional hedging rather than pure bearish conviction. Unusual volume spikes at specific strikes indicate active positioning on both sides.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.104159474 |
| Address1 | 94 Aeschengraben 27 |
| All Time High | 426.56 |
| All Time Low | 22.51 |
| Ask | 358.96 |
| Ask Size | 1 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 332,980 |
| Average Daily Volume3 Month | 388,700 |
| Average Volume | 388,700 |
| Average Volume10Days | 332,980 |
| Beta | 0.609 |
| Bid | 250.0 |
| Bid Size | 4 |
| Book Value | 45.779 |
| City | Basel |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Switzerland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 353.09 |
| Current Ratio | 3.405 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 354.39 |
| Day Low | 345.84 |
| Debt To Equity | 39.612 |
| Display Name | BeOne Medicines |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,931,200 |
| Earnings Call Timestamp Start | 1,785,931,200 |
| Earnings Growth | 1.667 |
| Earnings Quarterly Growth | 1.513 |
| Earnings Timestamp | 1,785,933,000 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | 1,071,609,024 |
| Ebitda Margins | 0.17483999 |
| Enterprise To Ebitda | 34.194 |
| Enterprise To Revenue | 5.979 |
| Enterprise Value | 36,642,537,472 |
| Eps Current Year | 7.64144 |
| Eps Forward | 10.25178 |
| Eps Trailing Twelve Months | 5.59 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 357.9309 |
| Fifty Day Average Change | -4.840912 |
| Fifty Day Average Change Percent | -0.01352471 |
| Fifty Two Week Change Percent | 10.415947 |
| Fifty Two Week High | 385.22 |
| Fifty Two Week High Change | -32.130005 |
| Fifty Two Week High Change Percent | -0.083406895 |
| Fifty Two Week Low | 253.948 |
| Fifty Two Week Low Change | 99.142 |
| Fifty Two Week Low Change Percent | 0.39040276 |
| Fifty Two Week Range | 253.948 - 385.22 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,454,509,800,000 |
| Float Shares | 80,959,148 |
| Forward Eps | 10.25178 |
| Forward P E | 34.441826 |
| Free Cashflow | 879,021,888 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 12,000 |
| Fullday Change | 4.01001 |
| Fullday Change Percent | 1.1480788 |
| Fullday Price | 353.09 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.88894 |
| Gross Profits | 5,448,286,208 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.17277001 |
| Held Percent Institutions | 0.33280998 |
| Implied Shares Outstanding | 113,768,498 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland. |
| Long Name | BeOne Medicines AG |
| Market | us_market |
| Market Cap | 40,170,516,480 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_115205344 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-14 |
| Net Income To Common | 655,707,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 42,287,435,420 |
| Number Of Analyst Opinions | 27 |
| Open | 346.05 |
| Operating Cashflow | 1,484,056,064 |
| Operating Margins | 0.19063999 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.74 |
| Phone | 41 61 685 19 00 |
| Prev Name | BeiGene, Ltd. |
| Previous Close | 349.08 |
| Price Eps Current Year | 46.20726 |
| Price Hint | 2 |
| Price To Book | 7.712925 |
| Price To Sales Trailing12 Months | 6.5542107 |
| Profit Margins | 0.106979996 |
| Quick Ratio | 2.911 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 4.01001 |
| Regular Market Change Percent | 1.1480788 |
| Regular Market Day High | 354.39 |
| Regular Market Day Low | 345.84 |
| Regular Market Day Range | 345.84 - 354.39 |
| Regular Market Open | 346.05 |
| Regular Market Previous Close | 349.08 |
| Regular Market Price | 353.09 |
| Regular Market Time | 1,791,992,023 |
| Regular Market Volume | 61,499 |
| Return On Assets | 0.07457 |
| Return On Equity | 0.14661999 |
| Revenue Growth | 0.296 |
| Revenue Per Share | 55.275 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 104,918,094 |
| Shares Percent Shares Out | 0.017 |
| Shares Short | 1,933,092 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,422,559 |
| Short Name | BeOne Medicines Ltd. |
| Short Percent Of Float | 0.0239 |
| Short Ratio | 4.96 |
| Source Interval | 15 |
| Symbol | ONC |
| Target High Price | 528.0 |
| Target Low Price | 370.0 |
| Target Mean Price | 435.53445 |
| Target Median Price | 439.41 |
| Total Cash | 5,098,040,832 |
| Total Cash Per Share | 44.837 |
| Total Debt | 2,049,524,992 |
| Total Revenue | 6,128,963,072 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 5.59 |
| Trailing P E | 63.164577 |
| Trailing Peg Ratio | 0.7722 |
| Triggerable | 1 |
| Two Hundred Day Average | 321.70453 |
| Two Hundred Day Average Change | 31.385468 |
| Two Hundred Day Average Change Percent | 0.09755992 |
| Type Disp | Equity |
| Volume | 61,499 |
| Website | https://beonemedicines.com |
| Zip | 4,051 |